术前纤维蛋白原联合中性粒细胞/淋巴细胞比值评分量表预测非典型脑膜瘤预后情况

摘要
图/表
参考文献(18)
相关文章 (15)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的通过外周血液指标建立并验证预测非典型脑膜瘤患者预后的评分量表。方法回顾性地纳入2010年1月～2017年6月广东三九脑科医院收治的行手术治疗的131例非典型脑膜瘤患者。术后随访通过复查磁共振观察患者有无复发，根据术后3年随访有无复发将其分为复发组与未复发组，其中复发组39例，未复发组92例。收集患者的临床、实验室指标、影像表现等相关性资料并分析其与肿瘤复发的关系。结果术前纤维蛋白原联合中性粒细胞/淋巴细胞比值（FIB-NLR）评分量表预测患者术后3年无进展生存期（PFS）的性能良好（曲线下面积为0.836）。多因素风险分析模型显示，FIB-NLR评分量表（1分：HR=4.90，95%CI=1.58～15.17，P=0.006；2分：HR=18.01，95%CI=5.75～56.42，P＜0.001）与患者术后3年PFS 独立相关。结论术前外周血FIB-NLR评分量表可以较准确地预测非典型脑膜瘤患者的预后情况，为辅助指导临床诊疗提供了新手段。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	叶景
	李业海
	林建浩
	何桂录
	黄佛宝
	李俏
	张良

关键词 ：非典型脑膜瘤, 纤维蛋白原, 中性粒细胞/淋巴细胞比值, 预测, 无进展生存, 预后

Abstract：Objective To establish and verify a scoring scale for predicting the prognosis of patients with atypical meningioma based on peripheral blood indicators.Methods A total of 131 patients with atypical meningioma admitted to Guangdong 999 Brain Hospital from January 2010 and June 2017 were enrolled in this retrospective study.Tumor relapse was observed by magnetic resonance imaging and patients were then classified into recurrence group and nonrecurrence group.There were 39 patients in recurrence group and 92 patients in non-recurrence group.The clinical,laboratory indicators,imaging manifestations and other relevant data were collected to analyze their relationship with tumor recurrence.Results The good performance of the fibrinogen and neutrophil-lymphocyte ratio (FIB-NLR) scoring scale for predicting 3-year progression-free survival (PFS) was showed (the area under curve=0.836).Multivariate Cox analysis revealed that FIB-NLR scoring scale (1 point: HR=4.90,95%CI=1.58-15.17,P=0.006;2 points: HR=18.01,95%CI=5.75-56.42,P＜0.001) remained independently related to 3-year PFS postoperatively.Conclusion Preoperative FIB-NLR scoring scale could predict prognosis of patients with atypical meningioma,providing a new tool for assisting clinical diagnosis and treatment

Key words： Atypical meningioma Fibrinogen Neutrophil-lymphocyte ratio Prediction Progression-free survival Prognosis

基金资助:广东省广州市科技计划项目（202002030309）

作者简介: 叶景，主要研究方向：脑肿瘤及脑血管疾病的手术治疗

引用本文:

叶景；李业海；林建浩；何桂录；黄佛宝；李俏；张良. 术前纤维蛋白原联合中性粒细胞/淋巴细胞比值评分量表预测非典型脑膜瘤预后情况[J]. 中国当代医药, 2020, 27(35): 16-19.
YE Jing ；LI Ye-hai ；LIN Jian-hao； HE Gui-lu ；HUANG Fo-bao； LI Qiao ；ZHANG Liang. Preoperative fibrinogen combined with neutrophil-lymphocyte ratio scoring scale to predict the prognosis of atypical meningioma. 中国当代医药, 2020, 27(35): 16-19.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I35/16

[1]	Aghi MK，Carter BS，Cosgrove GR，et al.Long-term recurrence rates of atypical meningiomas after gross total resection with or without postoperative adjuvant radiation[J].Neurosurgery，2009，64（1）：56-60.
[2]	Durand A，Labrousse F，Jouvet A，et al.WHO grade ⅡandⅢmeningiomas：a study of prognostic factors[J].J Neurooncol，2009，95（3）：367-375.
[3]	Mantovani A，Allavena P，Sica A，et al.Cancer-related inflammation[J].Nature，2008，454（7203）：436-444.
[4]	Qiu J，Yu Y，Fu Y，et al.Preoperative plasma fibrinogen，platelet count and prognosis in epithelial ovarian cancer[J].J Obstet Gynaecol Res，2012，38（4）：651-657.
[5]	Arigami T，Uenosono Y，Ishigami S，et al.A Novel Scoring System Based on Fibrinogen and the Neutrophil-Lymphocyte Ratio as a Predictor of Chemotherapy Response and Prognosis in Patients with Advanced Gastric Cancer[J].Oncology，2016，90（4）：186-192.
[6]	Wu Y，Song Z，Sun K，et al.A Novel Scoring System Based on Peripheral Blood Test in Predicting Grade and Prognosis of Patients with Glioma[J].Onco Targets Ther，2019，12：11 413-11 423.
[7]	Templeton AJ，McNamara MG，Seruga B，et al.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors：a systematic review and meta-analysis[J].J Natl Cancer Inst，2014，106（6）：dju124.
[8]	Louis DN，Ohgaki H，Wiestler OD，et al.The 2007 WHO classification of tumours of the central nervous system[J].Acta Neuropathol，2007，114（2）：97-109.
[9]	Louis DN，Perry A，Reifenberger G，et al.The 2016 World Health Organization Classification of Tumors of the Central Nervous System：a summary[J].Acta Neuropathol，2016，131（6）：803-820.
[10]	Liang RF，Li M，Li JH，et al.The significance of preoperative hematological inflammatory markers in patients with meningiomas[J].Clin Neurol Neurosurg，2019，182：1-4.
[11]	Stover JF，Hopf NJ，Perneczky A，et al.Unspecific metabolic blood parameters as used in clinical routine may differentiate malignant from benign cerebral tumors[J].Cancer Lett，1995，95（1-2）：147-152.
[12]	Shakir SI，Souhami L，Petrecca K，et al.Prognostic factors for progression in atypical meningioma[J].J Neurosurg，2018，129（5）：1240-1248.
[13]	Fernandez C，Nicholas MK，Engelhard HH，et al.An analysis of prognostic factors associated with recurrence in the treatment of atypical meningiomas[J].Adv Radiat Oncol，2016，1（2）：89-93.
[14]	Lee JH，Kim OL，Seo YB，et al.Prognostic Factors of Atypical Meningioma：Overall Survival Rate and Progression Free Survival Rate[J].J Korean Neurosurg Soc，2017，60（6）：661-666.
[15]	Barresi V，Lionti S，Caliri S，et al.Histopathological features to define atypical meningioma：What does really matter for prognosis?[J].Brain Tumor Pathol，2018，35（3）：168-180.
[16]	Barrett OC，Hackney JR，McDonald AM，et al.Pathologic Predictors of Local Recurrence in Atypical Meningiomas Following Gross Total Resection[J].Int J Radiat Oncol Biol Phys，2019，103（2）：453-459.
[17]	Hwang WL，Marciscano AE，Niemierko A，et al.Imaging and extent of surgical resection predict risk of meningioma recurrence better than WHO histopathological grade[J].Neuro Oncol，2016，18（6）：863-872.
[18]	Kasuya H，Kubo O，Tanaka M，et al.Clinical and radiological features related to the growth potential of meningioma[J].Neurosurg Rev，2006，29（4）：293-296；discussion 296-297.